echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Severe obesity impairs antibody response to COVID-19 vaccine, study shows

    Severe obesity impairs antibody response to COVID-19 vaccine, study shows

    • Last Update: 2022-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compared with normal-weight adults, severely obese adults ( 18 years or older) had a significantly weaker immune response to the COVID-19 vaccine


    The study also found that people with severe obesity (BMI over 40kg/m2) produced significantly more antibodies after receiving the Pfizer/BioNTech BNT162b2 mRNA vaccine than those receiving the coronavirus vaccine, suggesting that the Pfizer/BioNTech vaccine may be a better option for this vulnerable population select


    Obesity is a disease that complicates the course of COVID-19, and SARS-CoV-2 vaccine antibody responses in obese adults may be affected


    To learn more, the researchers surveyed 124 severely obese adults (average age 42-63) who visited Istanbul University's Cerrahpasa Obesity Center, Cerrahpaña Medical Faculty Hospitals, at Pfizer, between August and November 2021.


    The researchers measured antibody levels in blood samples from patients and normal-weight controls who received two doses of the Pfizer/Biotech or CoronaVac vaccine and a second dose four weeks earlier


    Overall, 130 participants received two doses of Pfizer/Biotech and 160 participants received two doses of CoronaVac, 70 of whom were previously infected with SARS-CoV-2 (see table in Editor's Notes)


    Among those who had not been infected with SARS-CoV-2 and had received the Pfizer/Biotech vaccine, severely obese patients had antibody levels more than three times lower than normal-weight controls (average 5823 vs 19371 AU/ml; note to editors) in Table 1)


    Likewise, among participants not previously infected with SARS-CoV-2 and vaccinated against the coronavirus, severely obese patients had 27-fold lower antibody levels than normal-weight controls (mean 178 vs 4894 AU/ml; in a note to the editor).


    However, among patients previously infected with SARS-CoV-2, antibody levels in severely obese patients and those vaccinated with Pfizer/Biotech or CoronaVac were not significantly different from normal-weight controls (mean 39043 vs 14,115 AU/ml and 3221 AU/ml vs.


    Interestingly, the analysis found that among severely obese patients, with or without previous SARS-CoV-2 infection, those vaccinated with Pfizer/Biotech had significantly higher levels of antibodies than those vaccinated with CoronaVac


    "These results provide new information on the antibody response to the SARS-CoV-2 vaccine in severely obese people and underscore the importance of prioritizing and increasing vaccine uptake in this vulnerable population," Professor Yumuk said



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.